Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall.
Tenreiro MM et al. Angiogenesis. 2017 Aug 24. doi: 10.1007/s10456-017-9571-8. [Epub ahead of print].
Intracellular light chain crystals in myeloma.
Staubach ZG et al. Blood. 2017 Aug 24;130(8):1070. doi: 10.1182/blood-2017-04-779207.
Logic programming reveals alteration of key transcription factors in multiple myeloma.
Miannay B et al. Sci Rep. 2017 Aug 23;7(1):9257. doi: 10.1038/s41598-017-09378-9.
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.
Kelly KR et al. Leukemia. 2017 Aug 23. doi: 10.1038/leu.2017.272. [Epub ahead of print].
Circulating resistin levels and risk of multiple myeloma in three prospective cohorts.
Santo L et al. Br J Cancer. 2017 Aug 22. doi: 10.1038/bjc.2017.282. [Epub ahead of print].
Neutral tumor evolution in myeloma is associated with poor prognosis.
Johnson DC et al. Blood. 2017 Aug 21. pii: blood-2016-11-750612. doi: 10.1182/blood-2016-11-750612. [Epub ahead of print].
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
Rasche L et al. Nat Commun. 2017 Aug 16;8(1):268. doi: 10.1038/s41467-017-00296-y.
Development of GLUT4-selective antagonists for multiple myeloma therapy.
Wei C et al. Eur J Med Chem. 2017 Aug 14;139:573-586. doi: 10.1016/j.ejmech.2017.08.029. [Epub ahead of print].
Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis.
Eleutherakis-Papaiakovou E et al. Bone Marrow Transplant. 2017 Aug 14. doi: 10.1038/bmt.2017.172. [Epub ahead of print].
STAT3-induced long noncoding RNAs in multiple myeloma cells display different properties in cancer.
Binder S et al. Sci Rep. 2017 Aug 11;7(1):7976. doi: 10.1038/s41598-017-08348-5.
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Gupta N et al. J Clin Pharmacol. 2017 Aug 11. doi: 10.1002/jcph.988. [Epub ahead of print].
LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma.
Yang N et al. Cell Death Dis. 2017 Aug 10;8(8):e2975. doi: 10.1038/cddis.2017.358.
Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma.
Rojas E et al. Clin Cancer Res. 2017 Aug 8. pii: clincanres.0678.2017. doi: 10.1158/1078-0432.CCR-17-0678. [Epub ahead of print].
TGF-β induces growth suppression in multiple myeloma MM.1S cells via E2F1.
Liu X et al. Oncol Lett. 2017 Aug;14(2):1884-1888. doi: 10.3892/ol.2017.6360. Epub 2017 Jun 9.
The effect of marrow stromal cells on TRAF6 expression levels in myeloma cells.
Huang H et al. Oncol Lett. 2017 Aug;14(2):1464-1470. doi: 10.3892/ol.2017.6322. Epub 2017 Jun 6.
Epigenetic silencing of LPP/miR-28 in multiple myeloma.
Li Z et al. J Clin Pathol. 2017 Aug 3. pii: jclinpath-2017-204501. doi: 10.1136/jclinpath-2017-204501. [Epub ahead of print].
Plasma cells with hairy projections and Auer rod-like inclusions in a patient with multiple myeloma.
Sharma P et al. BMJ Case Rep. 2017 Aug 3;2017. pii: bcr-2017-221315. doi: 10.1136/bcr-2017-221315.
Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma.
Handa H et al. Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14882. [Epub ahead of print].
Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma.
Chillón MC et al. Ann Hematol. 2017 Aug 2. doi: 10.1007/s00277-017-3083-x. [Epub ahead of print].
Clonal expansion and interrelatedness of distinct B-lineage compartments in multiple myeloma bone marrow.
Hansmann L et al. Cancer Immunol Res. 2017 Aug 2. pii: canimm.0012.2017. doi: 10.1158/2326-6066.CIR-17-0012. [Epub ahead of print].
Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.
Tokunaga E et al. PLoS One. 2017 Aug 1;12(8):e0182152. doi: 10.1371/journal.pone.0182152. eCollection 2017.
Enhancing ER stress in myeloma.
Wallington-Beddoe CT et al. Aging (Albany NY). 2017 Jul 30;9(7):1645-1646. doi: 10.18632/aging.101273.
Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets.
Kim EJ et al. Immunology. 2017 Jul 31. doi: 10.1111/imm.12804. [Epub ahead of print].
Response to “The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma”.
Xu XS et al. Clin Pharmacol Ther. 2017 Jul 29. doi: 10.1002/cpt.779. [Epub ahead of print].
Ru(ii)-(PTA) and -mPTA complexes with N2-donor ligands bipyridyl and phenanthroline and their antiproliferative activities on human multiple myeloma cell lines.
Wołoszyn A et al. Dalton Trans. 2017 Aug 14;46(30):10073-10081. doi: 10.1039/c7dt02051a. Epub 2017 Jul 21.